# ACGL (Arch Capital Group Ltd.) — Investment Committee Decision

## Date: 2026-02-14
## Pipeline Stage: R4 — Investment Committee (10 Gates)

---

## GATE 0: SECTOR VIEW EXISTS (HARD BLOCK)

- [X] Sector identified: Insurance
- [X] Glob match: `world/sectors/insurance.md` EXISTS
- [X] Sector view verified: insurance.md, updated 2026-02-13, status NEUTRAL
- **RESULT: PASS** — Proceed to gates.

---

## PASO 0.5: PRECEDENTES CONSULTADOS

### Most Similar Precedents

1. **ROP ($300 standing order, 2026-02-12):** Tier B (QS 48 tool / 70 adj), 22% MoS, 4% sizing, WIDE moat 20/25. Serial acquirer with goodwill distortion. APPROVED as standing order. Conviction LOW. Kill conditions 7. Valid until Q1 2026 earnings.
   - **Relevance to ACGL:** Same tier (B), same sizing (4%), similar MoS range (22% vs 20% for ACGL at $88). Both have QS tool distortion requiring documented adjustment. Both WIDE moat. Both entering cyclical headwinds (SaaSpocalypse for ROP, soft market for ACGL).

2. **MMC ($155 standing order, 2026-02-14):** Tier B (QS 68 adj), 18.4% MoS, HALF POSITION (EUR 200) due to Greensill binary event. Insurance broker, same sector view. APPROVED with conditions.
   - **Relevance to ACGL:** Same sector (insurance), same QS (68), same tier. MMC was sized at HALF because of a binary event (Greensill). ACGL has no comparable binary event, so full 4% sizing is defensible.

3. **GL ADD at $125 standing order:** Insurance sector, Tier B/C borderline (QS 52 adj 55). Standing order with adversarial pipeline. Same sector.
   - **Relevance to ACGL:** Same sector. GL is LOWER quality (QS 55 vs 68). ACGL represents a quality upgrade within insurance allocation per Principio 9.

4. **VLTO ($80 standing order, 2026-02-14):** Tier B (QS 66 adj), 20% MoS, 4% sizing. APPROVED.
   - **Relevance to ACGL:** Similar QS, similar MoS, similar sizing. Provides pattern confirmation.

5. **HRB BUY+ADD then SELL (Feb 2-9):** Tier B gone wrong. Pre-adversarial BUY at $35, SOLD at $32.77 (-13.25%). Lesson: Standing orders for non-Tier-A need adversarial pipeline.
   - **Relevance to ACGL:** ACGL HAS full adversarial pipeline (R1+R2+R3 complete). This distinguishes it from HRB. The standing order discipline is critical.

### Deviation Assessment

If I approve ACGL at $88 entry with 20% MoS, this is CONSISTENT with:
- ROP: 22% MoS, Tier B, WIDE moat, standing order → APPROVED
- VLTO: 20% MoS, Tier B, standing order → APPROVED
- MMC: 18.4% MoS, Tier B, HALF position (due to binary risk) → APPROVED

No deviation from precedents required.

---

## GATE 1: QUALITY SCORE (CRITICAL)

- [X] QS Tool: 57/100
- [X] QS Adjusted: 68/100 (Tier B)
- [X] Adjustment: +8 (ROIC→ROE for insurer, documented), +3 (GM trend data gap, documented)
- [X] Tier: B
- [X] NOT Tier D → Continue

**QS Tool-First compliance:**
- QS Tool: 57 (Tier B)
- QS Adjusted: 68 (Tier B) — adjustment +11 documented with per-item quantitative evidence
- Moat assessor suggested 78-82 (Tier A) — REJECTED by DA and orchestrator as exceeding +20 max adjustment and violating system's documented QS inflation pattern (Error #43)
- The 68 is conservative and appropriate. ACGL stays Tier B.

**RESULT: PASS** — QS 68, Tier B.

---

## GATE 2: ENTENDIMIENTO DEL NEGOCIO

- [X] Business Analysis Framework completed in thesis
- [X] Can explain in 2 minutes:

> Arch Capital is a Bermuda-based specialty insurer/reinsurer operating three platforms: Insurance (specialty P&C), Reinsurance (property cat, casualty, specialty), and Mortgage Insurance (US PMI). Revenue comes from insurance premiums collected upfront, with claims paid later — creating "float" that ACGL invests ($47B+ portfolio at ~4% yield). The core competitive advantage is underwriting DISCIPLINE: a 25-year culture of refusing to write unprofitable business, producing combined ratios 10-15pp below industry. This discipline has compounded book value at >15% CAGR since 2001 through multiple cycles. The stock is cheap (P/E 8.6x, P/B 1.53x) because the reinsurance cycle is softening (-14.7% prop cat rates at Jan 2026 renewals) and the market fears earnings compression.

- [X] Know WHY it's cheap + counter-thesis:
  - **Market says:** Reinsurance cycle softening will compress margins.
  - **I say:** ACGL navigated every soft market since 2001 by shedding unprofitable volume. The 82.8% CR provides 15+ points of buffer. Even bear case (95% CR, 12% ROE) produces book value growth.
  - **Counter:** ILS capital ($120B+) is structural and permanent, making this soft market potentially longer/deeper than prior ones. Social inflation is a blind spot.

- [X] Value Trap Checklist: 0.5/10 (very low risk)
  - Only partial flag: insider selling (Chairman $20M sale)

- [X] Informational advantage: Horizonte temporal + P/B framework insight + market overreaction to cycle

**RESULT: PASS** — Business well understood.

---

## GATE 3: PROYECCION FUNDAMENTADA

- [X] Revenue growth derived: -4% to +4% FY2026 (deliberate volume shedding), +5-8% FY2027-28 (cycle recovery)
- [X] WACC calculated: Ke = 6.3-6.6% (Rf 4.4% + Beta 0.38 x ERP 5.0%). ACGL is net cash, so WACC ~ Ke.
  - **Note:** Beta of 0.38 is LOW. DA flagged this. Using 0.6-0.7 would give Ke 7.4-7.9%. The R3 resolution uses practical P/B approach rather than relying on Gordon Growth (which is too sensitive to low beta).
- [X] Terminal growth: 3% (book value growth from reinvested earnings)
- [X] Scenarios documented:

| Scenario | Prob | CR | ROE | P/B | BVPS | FV |
|----------|------|-----|-----|-----|------|-----|
| Bear | 35% | 92-95% | 10-12% | 1.3x | $65 | $85 |
| Base | 40% | 86-90% | 13-15% | 1.7x | $65 | $110 |
| Bull | 25% | 80-84% | 18-20% | 2.2x | $65 | $143 |

Note: Bear probability increased from thesis 25% to 35% per DA recommendation and R3 resolution. Base ROE reduced from 15-17% to 13-15% per mid-cycle adjustment.

**RESULT: PASS** — Projections derived from business fundamentals.

---

## GATE 4: VALORACION MULTI-METODO

- [X] Method appropriate for Tier B Financial:
  - Tier B + Financial → P/B vs ROE (primary) + P/E normalized (secondary)

- [X] Method 1 (P/B vs ROE, 60%): FV $110
  - Mid-cycle ROE 13-15%, practical P/B 1.7x (R3-adjusted from 1.85x), BVPS $65.11
  - $65.11 x 1.7 = $111, rounded to $110

- [X] Method 2 (P/E Normalized, 40%): FV $108
  - R3-adjusted mid-cycle EPS $9.00 (down from $10.50, per DA recommendation of $8-9, weighted conservatively)
  - Fair P/E 12x (modest premium to historical 10-12x)
  - $9 x 12 = $108

- [X] Divergence: 2% ($110 vs $108) — EXCELLENT convergence

- [X] Weighted: ($110 x 0.60) + ($108 x 0.40) = $66 + $43.2 = **$109.20 → $110**

- [X] Expected Value: ($85 x 0.35) + ($110 x 0.40) + ($143 x 0.25) = $29.75 + $44 + $35.75 = **$109.50 → $110**

**R3 Resolution verified:** Analyst $120 → DA $105-110 → Orchestrator $110. Methods converge at $110.

**RESULT: PASS** — FV $110, two methods converge.

---

## GATE 5: MARGEN DE SEGURIDAD (RAZONADO v4.0)

- [X] Tier: B
- [X] MoS at $88 entry vs Base $110: **20%**
- [X] MoS at $88 entry vs Bear $85: **-3.4%**

**Razonamiento:**

20% MoS at $88 for a Tier B insurer entering a soft market. Is this adequate?

**Arguments FOR adequacy:**
1. ACGL has WIDE moat (22/25) — better than any Tier B in our system except ROP (20/25)
2. Net cash balance sheet provides capital safety cushion
3. Bear case ($85) is ~tangible book value — permanent capital loss risk is LIMITED
4. The business has navigated EVERY prior cycle successfully (15%+ BVPS CAGR through multiple soft markets)
5. Comparable precedents: ROP at 22% MoS APPROVED, VLTO at 20% MoS APPROVED

**Arguments AGAINST adequacy:**
1. We are entering at the START of a confirmed soft market — fundamentals may deteriorate for 2-4 years before recovery
2. Bear case MoS is -3.4% (negative) — if bear materializes, we lose money
3. Chairman just sold $20M in stock (NEGATIVE insider signal)
4. Social inflation is a documented gap in the thesis (partially unresolved)
5. DA says "better entry likely available in 12-18 months"

**Resolution:**
The 20% MoS at $88 is ADEQUATE but NOT exceptional. It is at the LOW END of Tier B precedent range (20-25%). The WIDE moat and net cash provide downside protection that makes the -3.4% bear case MoS less concerning than for a leveraged Tier B company. However, the timing risk (entering at soft market start) and the social inflation gap are real concerns.

**Precedent:** ROP was approved at 22% MoS with 2 CRITICAL risks (balance sheet fragility + DOGE structural). ACGL has 1 CRITICAL risk (reinsurance softening) and 2 HIGH risks (mega-cat, Bermuda tax). Risk profile is comparable. If ROP at 22% MoS was approved, ACGL at 20% MoS is consistent — especially given ACGL's net cash (vs ROP's high leverage).

**RESULT: PASS** — 20% MoS adequate for Tier B with WIDE moat, net cash, and proven cycle management. Standing order at $88 provides price discipline.

---

## GATE 6: CONTEXTO MACRO

- [X] World view reviewed: 2026-02-11
- [X] Cycle: Mid-cycle US, labor market resilient, inflation sticky
- [X] Fit empresa-ciclo:
  - Insurance is NEUTRAL-to-FAVORABLE in mid-cycle with elevated rates
  - Fed on hold at 3.5-3.75% → investment income remains strong for ACGL's $47B float
  - Inflation sticky → insurance companies can reprice (but social inflation also pressures claims)
  - US geographic exposure is DIVERSIFYING (portfolio currently EU-heavy)
- [X] Megatendencies: Climate change is secular tailwind for insurance TAM (more risk to insure) but also increases cat losses. AI is POSITIVE for insurance (claims processing, underwriting analytics).

**RESULT: PASS** — Macro neutral-favorable.

---

## GATE 7: PORTFOLIO FIT (RAZONADO v4.0)

**Constraint checker output (CHECK ACGL 400):**
- Position post-purchase: 4.0% → Coherent with Tier B precedents (ROP 4%, VLTO 4%, DSY.PA 4%)
- Sector Financial Services post-purchase: 18.5% → Currently 14.5% (ALL 3.5% + GL 3.6% + EDEN.PA 4.0% + MONY.L 3.4%). Adding ACGL 4% = 18.5%.

**Sector concentration reasoning:**
Financial Services at 18.5% includes heterogeneous businesses:
- ALL: US personal P&C insurance
- GL: US life/health insurance
- EDEN.PA: French employee benefits (NOT insurance underwriting)
- MONY.L: UK price comparison platform (NOT insurance underwriting)
- ACGL: Bermuda specialty/reinsurance

These businesses have LOW cross-correlation. EDEN.PA and MONY.L are NOT underwriters — they have zero claims risk. True insurance underwriting exposure: ALL (3.5%) + GL (3.6%) + ACGL (4.0%) = 11.1%. This is reasonable.

- Geography US post-purchase: 18.5% → Currently 14.5% (ADBE + GL + ALL + LULU). Adding ACGL 4% brings US to 18.5%. This is FAVORABLE given current UK (14.5%) and EU (14.0%) balance.
- Cash post-purchase: 53.0% (EUR 5,352) → Still very high. Principio 4: Cash is a position. At 53%, we have ample dry powder for other standing orders (ROP, MMC, DSY.PA, DNLM.L, VLTO).
- Correlation with existentes: LOW-MEDIUM. ACGL is a Bermuda specialty reinsurer — it correlates with insurance cycle, not with tech (ADBE, BYIT.L), consumer (LULU, DOM.L), or telecom (DTE.DE). Moderate correlation with ALL and GL only.

**50% drawdown test:** If ACGL falls 50%, portfolio impact = -2.0%. Coherent with 4% sizing and Tier B conviction.

**Quality Gravitation (Principio 9):** ACGL (QS 68) is HIGHER quality than both existing insurance positions: ALL (QS 56, ON PROBATION) and GL (QS 52). Adding ACGL does NOT degrade portfolio quality — it improves insurance sector quality. If capital needed later, ALL (the lowest quality position on probation) is the rotation candidate, not ACGL.

**RESULT: PASS** — Portfolio fit is favorable on all dimensions.

---

## GATE 8: SECTOR UNDERSTANDING

- [X] Sector view exists: world/sectors/insurance.md
- [X] Sector view reviewed: 2026-02-13
- [X] TAM and trends understood: Global P&C $2.5T, reinsurance ~$400B, both growing. Softening confirmed with -14.7% prop cat rates.
- [X] Disruption risks: AI is opportunity (not threat) for incumbents. InsurTech pivoted to partnerships. Climate is the main structural risk.
- [X] Sector position: NEUTRAL (stock picking selective)
- [X] ACGL identified in sector view as "top insurance UNDERWRITER pick"

**RESULT: PASS** — Sector well understood.

---

## GATE 9: AUTOCRITICA

**Assumptions not validated:**
1. Mid-cycle ROE of 13-15% assumes soft market is manageable. If ILS capital makes this cycle structurally different, ROE could stay at 10-12% longer.
2. Social inflation impact on ACGL's casualty reserves is UNKNOWN (thesis gap). Partially mitigated by acknowledging it as a risk, but not quantified.
3. New CEO Papadopoulo will maintain discipline — only 18 months of track record as CEO.

**Biases recognized:**
- [X] Popularity bias: LOW. ACGL is not a household name. It came through sector screening, not familiarity.
- [X] Confirmation bias: MEDIUM. After reading the thesis (which is bullish), I may be anchoring to the bull case. The DA's MODERATE COUNTER and the R3 FV reduction ($120→$110) partially correct this.
- [X] Recency bias: MEDIUM. FY2025 was exceptional (22.6% BVPS growth). I must not anchor to peak-cycle results. The mid-cycle adjustment addresses this.

**Kill conditions (7):**
1. Combined ratio >100% for 2 consecutive years
2. ROE <10% for 2 consecutive years
3. Management abandons underwriting discipline (premium growth while CR deteriorates)
4. Major adverse reserve development (>10% book value hit)
5. Mortgage insurance book impairment (2008-style)
6. Share buybacks at elevated P/B (>2.5x) while margins deteriorate
7. BVPS declines for 2 consecutive years (excluding major cat years)

**What would make me change my mind:**
- If social inflation investigation reveals ACGL has >40% of reserves in casualty/liability with adverse development on 2019-2021 accident years → would REDUCE conviction further
- If Q1 2026 results show CR >90% ex-cat → soft market hitting faster than expected → would LOWER entry to $82
- If a second insider (CEO or CFO) sells >$5M → insider signal becomes STRONGLY NEGATIVE → would REDUCE sizing

**RESULT: PASS** — Self-criticism documented, kill conditions defined.

---

## GATE 10: COUNTER-ANALYSIS & INDEPENDENT ASSESSMENTS

**Counter-analysis exists?** YES — `thesis/research/ACGL/devils_advocate.md`

- [X] DA Verdict: MODERATE COUNTER (12/19, later updated to 13/19 in final score)
- [X] HIGH/CRITICAL challenges: 6 of 19 total

**For EACH HIGH/CRITICAL challenge:**

| # | Challenge | Thesis Addresses? | Resolution |
|---|-----------|-------------------|------------|
| 1 | FV $120 above all analyst targets | PARTIALLY — acknowledged but not adjusted | RESOLVED in R3: FV reduced to $110. Still slightly above consensus $108.67 but within range (Wells Fargo $109, RBC $115). |
| 2 | P/B base 1.85x exceeds 5yr median 1.64x | PARTIALLY — acknowledged historical range | RESOLVED in R3: P/B reduced to 1.7x (closer to median). Premium justified by ROE >> peers. |
| 3 | Social inflation missing from thesis | NOT addressed in thesis | PARTIALLY RESOLVED: Acknowledged as HIGH-severity risk in risk assessment. Exact casualty reserve composition unknown. ACCEPTED as known risk — documented as a gap. The standing order at $88 (not current price) provides buffer. ACGL's track record of favorable development ($167M in Q1 2025) is evidence of conservative reserving, though not proof of immunity. |
| 4 | Chairman $20M stock sale classified NEUTRAL | NOT properly addressed | RESOLVED in R3: Reclassified from NEUTRAL to NEGATIVE. Factored into bear case probability increase (25%→35%). Not a kill condition, but a yellow flag. |
| 5 | Timing at START of soft market | ACKNOWLEDGED but entry still at $92 | RESOLVED in R3: Entry lowered from $92 to $88. Standing order provides price discipline — we do NOT buy at current price. If price reaches $88 during soft market, it means the market has further discounted cycle risk. |
| 6 | Normalized EPS $10.50 too high | NOT adjusted in original thesis | RESOLVED in R3: Mid-cycle EPS reduced to $9.00 per DA recommendation. P/E method now uses $9 x 12 = $108. |

**Unresolved CRITICAL challenges:** NONE. All 6 HIGH/CRITICAL challenges either resolved or accepted with documentation.

**Social inflation note:** This is the ONE gap that remains partially unresolved. However:
- It is documented as a HIGH-severity risk
- ACGL's 25-year track record of favorable reserve development provides evidence (not proof) of conservative reserving
- The standing order at $88 (20% MoS) provides buffer for this uncertainty
- Kill condition #4 (major adverse reserve development >10% BV) captures the tail risk
- Requiring FULL resolution of social inflation before any investment would mean NO insurance company could ever pass committee, as this is an industry-wide issue

I ACCEPT social inflation as a documented, unresolved risk. It is NOT a gate blocker because: (a) it is industry-wide, not ACGL-specific, (b) ACGL has the best track record in the industry of conservative reserving, and (c) the standing order provides price discipline.

**Moat assessment exists?** YES — `thesis/research/ACGL/moat_assessment.md`
- [X] Classification: WIDE (22/25)
- [X] Moat assessment QS (78-82) diverges from thesis QS (68) → Thesis QS is correct. Moat assessor exceeded +20 max adjustment. Committee maintains QS 68.

**Risk assessment exists?** YES — `thesis/research/ACGL/risk_assessment.md`
- [X] Risk Score: MEDIUM
- [X] Risks not in thesis: Social inflation (now documented), DTA amortization cliff (now documented)
- [X] Kill conditions from risk assessment incorporated into thesis kill conditions? YES — all 7 kill conditions cover the risk assessment's suggestions.

**Conflicts unresolved:** Social inflation reserve composition (accepted as known risk). No other conflicts.

**RESULT: PASS** — DA MODERATE COUNTER with all HIGH/CRITICAL challenges resolved or documented.

---

## VEREDICTO

### RECOMENDACION: STANDING ORDER — BUY EUR 400 of ACGL at $88 (4% del portfolio)

**10 Gates Summary:**

| Gate | Result | Key Finding |
|------|--------|-------------|
| 0. Sector View | PASS | insurance.md exists, updated 2026-02-13 |
| 1. Quality Score | PASS | QS 68/100 Tier B (tool 57, +11 adj documented) |
| 2. Business Understanding | PASS | Business well understood, 0.5/10 value trap |
| 3. Projection | PASS | Derived from cycle analysis, 3 scenarios |
| 4. Valuation | PASS | FV $110, two methods converge (2% divergence) |
| 5. MoS | PASS | 20% at $88, adequate for Tier B with WIDE moat |
| 6. Macro | PASS | Mid-cycle US, elevated rates favorable for float |
| 7. Portfolio Fit | PASS | 4% sizing, insurance 11.1% true underwriting, cash 53% post |
| 8. Sector | PASS | NEUTRAL sector, ACGL is top underwriter pick |
| 9. Autocritica | PASS | 7 kill conditions, 3 biases acknowledged |
| 10. Counter-Analysis | PASS | MODERATE COUNTER, all HIGH challenges resolved or documented |

**Decision:**

```
STANDING ORDER: BUY EUR 400 of ACGL at $88 (~4.0% del portfolio)

Quality Score: 68/100 → Tier B (tool 57, adj +11 for insurer structural distortion)
Fair Value: $110 (R3-resolved, was $120 analyst, DA pushed to $105-110)
Entry: $88 (20% MoS — low end of Tier B range, justified by WIDE moat + net cash)
Current Price: $98.38 (distance to entry: 10.6%)
Categoria: Quality Value — Best-in-class specialty insurer/reinsurer
Moat: WIDE (22/25) — Underwriting discipline culture + intangible assets
Risk: MEDIUM (1 CRITICAL: reinsurance softening, 2 HIGH: mega-cat, Bermuda tax)
Conviction: MEDIUM-LOW (soft market timing + social inflation gap temper conviction)

Kill Conditions:
1. Combined ratio >100% for 2 consecutive years
2. ROE <10% for 2 consecutive years
3. Management abandons underwriting discipline
4. Major adverse reserve development >10% BV
5. Mortgage insurance impairment (2008-style)
6. Buybacks at P/B >2.5x while margins deteriorate
7. BVPS declines 2 consecutive years (ex major cat)

Standing Order Validity: Until Q2 2026 earnings (July 2026)
  — If price has not reached $88 by then, re-evaluate with new cycle data

Precedent Sizing: ROP 4% (Tier B, WIDE moat, standing order), VLTO 4% (Tier B, standing order)
No deviation from precedents.
```

**Why STANDING ORDER at $88, not BUY NOW at $98.38?**

1. Current MoS at $98.38 is only 10.5% vs FV $110 — below Tier B pattern (20-25%)
2. We are at the START of a confirmed soft market — fundamentals may deteriorate further
3. Chairman sold $20M of stock recently — NEGATIVE insider signal
4. DA explicitly recommends "better entry likely available in 12-18 months"
5. Standing order provides PRICE DISCIPLINE — if $88 is reached, the market will have further discounted cycle risk, which actually INCREASES our confidence that the risk is priced
6. With 57% cash, there is no urgency to deploy at suboptimal entry

**Why NOT reject or delay further?**

1. Full buy-pipeline completed (R1+R2+R3 complete, all 6 output files exist)
2. The business quality is genuine — WIDE moat, 15%+ BVPS CAGR since 2001, net cash
3. Standing order at $88 is risk-managed — we only buy if the market gives us the price
4. ACGL is the highest-quality insurance company in our pipeline (QS 68 vs ALL 56, GL 52)
5. Precedent: ROP, VLTO, DSY.PA all approved as standing orders with similar profiles

---

## META-REFLECTION

### Dudas sobre esta decision
- Social inflation remains a partially unresolved gap. If ACGL's casualty reserves prove inadequate, the bear case worsens materially. However, requiring full resolution of an industry-wide issue before any investment would be paralysis.
- The Chairman's $20M sale could be a 10b5-1 pre-planned transaction (less concerning) or discretionary (very concerning). I could not confirm which. If discretionary, it would warrant further investigation before executing even at $88.
- The mid-cycle ROE of 13-15% is an assumption. If ILS capital structurally compresses reinsurance ROE to 10-12%, the fair value drops to $85-90 and the standing order at $88 would have only 0-2% MoS.

### Debilidades del analisis recibido
- The thesis was well-constructed but overvalued ACGL at $120 (above all analyst targets). The R3 correction to $110 is appropriate but still slightly above consensus $108.67.
- Social inflation was completely absent from the thesis — the DA correctly identified this as a material gap. However, the risk assessment mentions it only in passing. No agent performed a deep dive on ACGL's casualty reserve composition.
- The moat assessment was excellent in quality but pushed QS to 78-82, which would have made ACGL Tier A. The DA correctly challenged this, and I maintain QS 68 (Tier B).
- Beta of 0.38 makes WACC artificially low. The thesis acknowledges this but does not adjust. The R3 resolution handles it by using practical P/B rather than Gordon Growth (which is hyper-sensitive to WACC).

### Sugerencias de mejora
- **quality_scorer.py --insurer flag**: The tool systematically underscores ALL insurance companies. This has been flagged by the thesis analyst, moat assessor, risk assessor, AND DA. Priority: HIGH.
- **Social inflation as standard risk factor**: Should be added to risk-identifier checklist for ANY company with casualty/liability insurance exposure.
- **Cycle position field in quality universe**: For cyclical businesses (insurance, commodities, banking), a "cycle_position" field (early/mid/peak/early-soft/deep-soft) would help prevent buying at peaks.

### Preguntas para Orchestrator
- None. This decision is self-contained. The standing order at $88 provides adequate risk management, and the full buy-pipeline was completed.

---

## Consistency Check

| Dimension | This Decision | Precedent | Consistent? |
|-----------|---------------|-----------|-------------|
| Tier B MoS | 20% at $88 | ROP 22%, VLTO 20% | YES |
| Tier B Sizing | 4% | ROP 4%, VLTO 4%, DSY.PA 4% | YES |
| Standing order format | Price trigger + validity | ROP, DSY.PA, DNLM.L | YES |
| Kill conditions | 7 defined | ROP 7, VLTO 6 | YES |
| DA resolution | All HIGH challenges addressed | ROP, VLTO pattern | YES |
| Adversarial pipeline | Full R1-R3 completed | Required for all standing orders (HRB lesson) | YES |

No deviation from precedents. Decision is consistent with Framework v4.0.
